Prevention of osteoporotic fractures in post-menopausal women

Denosumab for the prevention of osteoporotic fractures in post-menopausal women (Single Technology Assessment for NICE)

This project was carried out as part of the National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal Process. The manufacturer of denosumab (Amgen UK Ltd) submitted an evidence review and an economic model assessing the cost-effectiveness of denosumab against a range of treatment comparators. The Aberdeen HTA group were commissioned to act as the Evidence Review Group (ERG) for the project, and to provide an independent report reviewing the manufacturer’s evidence submission.

Outcome and Translation

Following the ERG report, denosumab was recommended by NICE as a treatment option for the primary prevention of osteoporotic fragility fractures only in post-menopausal women at increased risk of fractures, and only amongst those unable to tolerate or comply with oral bisphosphonates, or where their use is contraindicated.

NICE (2010) NICE technology appraisal guidance 204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women, London: NICE.

HERU researchers involved in this research project: Graham Scotland and Paul McNamee

External Collaborators: N Waugh (Warwick University); P Royale, R Henderson, (Highland Health Board) and R Hollick (NHS Grampian)

Publications

Scotland, G., Royle, P., Henderson, R., Hollick, R., McNamee, P. and Waugh, N. (2010) Evidence Review Group: denosumab for the prevention of osteoporotic fractures in post-menopausal women. Final report submitted to the National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence.

Scotland, G., Waugh, N., Royle, P., McNamee, P., Henderson, R. and Hollick, R. (2011) 'Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal', Pharmacoeconomics, 29(11), 951-961.

Waugh, N., Royle, P., Scotland, G., Henderson, R., Hollick, R. and McNamee, P. (2011) 'Denosumab for the prevention of osteoporotic fractures in postmenopausal women', Health Technology Assessment, 15(Suppl 1), 51-9.

Scotland, G., Waugh, N., Royle, P., McNamee, P., Henderson, R. and Hollick, R. (2012) 'Denosumab per la prevenzione delle fratture osteoporotiche in donne in post-menopausa', PharmacoEconomics - Italian Research Articles, 14(2), 131-142.

Presentations

Scotland, G., Royle, P., Hendersen, R., Hollick, R., McNamee, P. and Waugh, N. (2010) 'Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a single technology appraisal', NICE appraisal committee meeting, Manchester, April 2010.